Netherlands, Bussum, December 13: Bentham Science Publishers has completed an agreement with Kobo Inc. to sell its E-books content on the Kobo platform and associated resellers. Some E-books will be available at the Kobo store from December 2014 with more titles scheduled in 2014. This agreement represents a new step forward for Bentham E-books as the publisher is transitioning towards publishing EPUB Books tailored for multiple platforms. Bentham Science Publishers E-books will be sold via Kobo in addition to Amazon KindleTM, Barnes & Noble and other reputable E-book stores.

A reputable journal publisher of over 130 online and print subscription journals, over 150 open access journals, and 350 e-books.

Some leading journals include Current Gene Therapy (Impact Factor 5.318) and Current Drug Metabolism (Impact Factor 4.405). Other high profile journals include Current Molecular Medicine (Impact Factor 4.197), Current Medicinal Chemistry (Impact Factor 4.07), Current Cancer Drug Targets (Impact Factor 4.00) and Current Drug Targets (Impact Factor 3.848).

Bentham E- Books also provide professionals, academicians, corporate researchers, graduates and under-graduates worldwide with the most current information in their subject areas of interest. For details: www.benthamscience.com

Founded in December 2009, Toronto-based Kobo has quickly become a global leader in eReading, offering a world-class platform for the most passionate Readers. Our mission is to lead the global transformation in reading by inspiring people to read more and more often – anytime, anyplace, anywhere around the world. Kobo delivers the best digital reading experience to millions of users in 190 countries, offering one of the world's largest catalogues with millions of titles, world-class eReading devices, and top-ranking apps. Kobo is owned by Tokyo-based eCommerce company Rakuten.

For details: www.kobo.com